Pegfilgrastim Side Effects
Some side effects of pegfilgrastim may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to pegfilgrastim: subcutaneous solution
Along with its needed effects, pegfilgrastim may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pegfilgrastim:More common
- sore throat
- ulcers; sores, or white spots in the mouth
- Bluish lips or skin
- pain, left upper abdomen or shoulder
- shortness of breath
- tightness in the chest
- troubled breathing
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- difficulty with swallowing
- fast heartbeat
- flushing or redness of the skin
- hives or welts
- itching, puffiness, or swelling of the eyelids or around the eyes, face, lips, or tongue
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- skin rash
- sores on the skin
- unusual tiredness or weakness
- unusually warm skin
Some side effects of pegfilgrastim may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Abdominal or stomach pain
- acid or sour stomach
- bone pain
- change in sense of taste
- cracked lips
- hair loss or thinning of hair
- joint pain
- lack or loss of strength
- loss of appetite
- muscle soreness
- stomach discomfort, upset, or pain
- swelling of the hands, ankles, feet, or lower legs
- swelling or inflammation of the mouth
- trouble sleeping
- weakness, generalized
- weight loss
- Body produces substance that can bind to drug making it less effective or cause side effects
For Healthcare Professionals
Applies to pegfilgrastim: subcutaneous solution
Musculoskeletal side effects associated with the administration of pegfilgrastim have included medullary bone pain, occurring in 26% of clinical trials patients.
Metabolic side effects associated with the administration of pegfilgrastim have included reversible elevations in LDH (19%), alkaline phosphatase (9%), and uric acid (8%). Treatment intervention was not necessary.
Hematologic side effects including splenic rupture have been reported rarely following the administration of filgrastim (the parent compound of pegfilgrastim) when used for peripheral blood progenitor cell mobilization in both healthy donors and patients with cancer. The administration of pegfilgrastim has been associated with asymptomatic leukocytosis (less than 1 %).
Pegfilgrastim should not be used for peripheral blood progenitor cell mobilization. Patients receiving pegfilgrastim who report left upper abdominal or shoulder tip pain should be evaluated for an enlarged spleen or splenic rupture.
General side effects associated with the administration of pegfilgrastim have included many effects that have been associated with the chemotherapy that was given concomitantly. These have included nausea, fatigue, alopecia, diarrhea, vomiting, constipation, fever, anorexia, skeletal pain, headache, taste perversion, dyspepsia, myalgia, insomnia, abdominal pain, arthralgia, generalized weakness, peripheral edema, dizziness, granulocytopenia, stomatitis, mucositis, and neutropenic fever. Most of these effects have been attributed by the investigators to be the result of the underlying condition or the chemotherapy administered.
Respiratory side effects including adult respiratory distress syndrome (ARDS) has been reported with the use of filgrastim (the parent compound of pegfilgrastim).
Because adult respiratory distress syndrome (ARDS) has been reported with the use of filgrastim, patients receiving pegfilgrastim who develop fever, lung infiltrates, or respiratory distress should be evaluated for the possibility of ARDS.
More pegfilgrastim resources
- pegfilgrastim MedFacts Consumer Leaflet (Wolters Kluwer)
- pegfilgrastim Subcutaneous Advanced Consumer (Micromedex) - Includes Dosage Information
- Pegfilgrastim Professional Patient Advice (Wolters Kluwer)
- Pegfilgrastim Monograph (AHFS DI)
- Neulasta Prescribing Information (FDA)
- Neulasta Consumer Overview
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.